The U.S. Food and Drug Administration disclosed a second wave of Commissioner’s National Priority Vouchers (CNPVs), accelerating review for selected drug candidates aligned with administration priorities. The agency named six additional winners in the program designed to shorten regulatory timelines; oral obesity candidates from Eli Lilly and Novo Nordisk were included in the list. The vouchers grant faster review windows and are intended to support access and domestic manufacturing goals articulated by the administration. Clarification: a Commissioner’s National Priority Voucher guarantees an expedited regulatory review window for a specified submission.